title: KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Disease Progression or Death Versus Chemotherapy With or Without Bevacizumab in Certain Patients With Platinum-Resistant Recurrent Ovarian Cancer
source: Yahoo
date: 2025-10-18
url: https://finnhub.io/api/news?id=5e28a92f2e8a22f4111f90e97e9c5ce04ff869c0f1192dcaf22e18fffc6311b4
RAHWAY, N.J., October 18, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from the pivotal Phase 3 KEYNOTE-B96 trial, also known as ENGOT-ov65, evaluating KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with chemotherapy (paclitaxel) with or without bevacizumab for the treatment of patients with platinum-resistant recurrent ovarian cancer. These late-breaking data will be presented today during
